Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI‐HF and Val‐HeFT trials
Open Access
- 22 February 2015
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 17 (4), 424-433
- https://doi.org/10.1002/ejhf.240
Abstract
Aims Uncertainties remain on the biological and prognostic significance and therapeutic implications of loss in body weight (W‐LOSS) in chronic heart failure (HF) patients. We assessed whether W‐LOSS added additional prognostic value to classical clinical risk factors in two separate and large cohorts of patients with chronic HF. The factors associated with W‐LOSS were studied. Methods and results W‐LOSS and estimated plasma volume changes were measured serially in the GISSI‐HF (n = 6820) and Val‐HeFT trials (n = 4892). In both studies, experiencing at least one episode of ≥5% W‐LOSS during the first year of follow‐up was considered a sign of wasting. In GISSI‐HF, self‐reported unintentional W‐LOSS ≥2 kg between two consecutive clinical visits within 1 year was also considered a sign of wasting. W‐LOSS occurred in 16.4% and 15.7% of the patients enrolled in GISSI‐HF and Val‐HeFT, respectively (unintentional ≥2 kg W‐LOSS occurred in 18.9% in GISSI‐HF). In multivariable analyses adjusting for a number of baseline covariates as well as for plasma volume changes, W‐LOSS was found to be independently associated with mortality and adverse cardiovascular and non‐cardiovascular outcomes, with a significant net reclassification improvement (cfNRI) and an increase in integrated discrimination improvement (IDI). W‐LOSS was independently associated with several features representing the severity of HF, including baseline NT‐proBNP and high sensitivity C‐reactive protein (hsCRP) in Val‐HeFT. Conclusions W‐LOSS was a frequent finding in the GISSI‐HF and Val‐HeFT trials, associated with multiple patient features, and added additional prognostic information beyond clinical variables of HF severity, including estimated plasma volume changes.Keywords
Funding Information
- Reagents for measuring NT-proBNP in Val-HeFT and GISSI-HF were kindly provided by Roche Diagnostics GmbH.
- the European Commission’s Seventh Framework Programme (under grant agreement No. 305507 (HOMAGE))
- The GISSI-HF trial was supported by grants from Società Prodotti Antibiotici (SPA, Italy), Pfizer, Sigma Tau and AstraZeneca.
- The Val-HeFT trial was funded by Novartis Pharmaceuticals (Switzerland).
This publication has 30 references indexed in Scilit:
- Mechanisms for Cachexia in Heart FailureCurrent Heart Failure Reports, 2013
- Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiologyInternational Journal of Cardiology, 2013
- Obesity and Cardiovascular DiseaseJournal of the American College of Cardiology, 2009
- Cardiac cachexia: A systematic overviewPharmacology & Therapeutics, 2008
- Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEuropean Heart Journal, 2008
- Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational studyThe Lancet, 2003
- The regulation and measurement of plasma volume in heart failureJournal of the American College of Cardiology, 2002
- The relationship between obesity and mortality in patients with heart failureJournal of the American College of Cardiology, 2001
- Wasting as independent risk factor for mortality in chronic heart failureThe Lancet, 1997
- “WATER DIURESIS” PRODUCED DURING RECUMBENCY BY THE INTRAVENOUS INFUSION OF ISOTONIC SALINE SOLUTION 1JCI Insight, 1951